Tesamorelin 50mg — Vial Spec, Reconstitution Math & COA

Overview of Tesamorelin 50mg Format & Platform Availability

A 50mg vial of Tesamorelin contains 50 milligrams of purified, lyophilized hexenoyl-GHRH peptide cake designed exclusively for in vitro and preclinical laboratory research. High-mass configurations are typically specified by academic research institutions, contract research organizations (CROs), and laboratory groups conducting multi-subject rodent assays or longitudinal receptor binding studies where consistent batch parameters across extended timelines are critical.

While bulk 50mg configurations serve specialized high-throughput workflows, standard experimental runs frequently utilize smaller unit sizes to minimize repetitive freeze-thaw degradation. Currently, PX1 Research provides the fully verified Tesamorelin 10mg single-vial format, which offers optimized unit volumes for standard assay series without risking peptide stability over prolonged fluid storage. Researchers requiring larger total active masses for extensive multi-animal or cell culture cohorts can review our complete catalog of all peptides or establish bulk provisioning arrangements through enterprise supply workflows.

Molecular Profile and Mechanism as a GHRH Analog

Tesamorelin is a synthetic 44-amino acid polypeptide derivative of human growth hormone-releasing hormone (GHRH(1-44)). The structural hallmark of Tesamorelin is the conjugation of a trans-3-hexenoic acid group to the N-terminal tyrosine residue. This N-terminal hydrophobic modification significantly enhances enzymatic stability against dipeptidyl peptidase-4 (DPP-IV) cleavage relative to endogenous GHRH, extending the biological half-life of the molecule in experimental media.

Preclinical studies suggest that Tesamorelin selective binds to and activates the GHRH receptor (GHRHR) on pituitary somatotrophs. Activation of GHRHR initiates a G-protein-coupled signal transduction cascade that stimulates endogenous growth hormone (GH) synthesis and pulsatile release. In animal models and cellular cultures, this targeted GH elevation downstream drives hepatic production of insulin-like growth factor 1 (IGF-1), making the compound a fundamental tool in research investigating metabolic regulation, lipid turnover, muscular cellular adaptation, and somatic tissue repair mechanisms.

Reconstitution Mathematics for 50mg Mass Formulations

Accurate volumetric calculation is essential when solubilizing high-mass cakes like tesamorelin 50mg to ensure precise volumetric aliquoting and reproducible target working concentrations. Due to the substantial peptide mass (50,000 micrograms), selecting an appropriate diluent volume directly dictates solution viscosity and concentration per micro-liter (µL). Researchers should utilize sterile bacteriostatic water (0.9% benzyl alcohol) or sterile isotonic saline depending on downstream assay compatibility.

When calculating working solutions, the total mass (50,000 µC / 50 mg) is divided by the total diluent volume added to the vial. To eliminate calculation errors across variable experimental setups, lab managers frequently utilize our automated reconstitution calculator. Standard dilution ratios for a 50mg vial yield the following technical metrics:

• 1.0 mL Diluent Volume: Yields a concentration of 50.0 mg/mL (50.0 µg per 1 µL). Note that high peptide density at 50mg/mL may require gentle agitation and extended dissolution time to achieve complete clarity without introducing shear stress.

• 2.0 mL Diluent Volume: Yields a concentration of 25.0 mg/mL (25.0 µg per 1 µL). This represents a highly functional concentration for serial micro-dilutions in microtiter plate assays.

• 3.0 mL Diluent Volume: Yields a concentration of 16.67 mg/mL (16.67 µg per 1 µL). Provides a manageable working viscosity for automated liquid handling systems and precise small-animal volumetric administration.

• 5.0 mL Diluent Volume: Yields a concentration of 10.0 mg/mL (10.0 µg per 1 µL). Recommended for large-scale multi-subject protocols where precise micro-dosing requires lower mass density per volumetric unit.

Aliquot Planning & Freeze-Thaw Degradation Protocols

Solubilized peptides undergo progressive hydrolytic and oxidative degradation when maintained in aqueous solution over extended timeframes, even under refrigeration (2°C–8°C). When reconstituting a high-yield vial such as tesamorelin 50mg, establishing a strict aliquoting procedure immediately after complete dissolution is vital for maintaining structural peptide integrity across long-term study schedules.

After complete dissolution, the primary stock solution should be divided into single-use or single-assay micro-centrifuge tubes (e.g., polypropylene micro-aliquots of 50 µL to 200 µL) inside a laminar flow cabinet. These sub-aliquots must be immediately flash-frozen at -20°C or -80°C. Repeated freeze-thaw cycles subject the polypeptide backbone to ice-crystal shear forces and localized pH fluctuations during phase transition, causing rapid peptide aggregation and loss of GHRHR binding affinity. Each individual aliquot should be thawed once, maintained at 4°C during active assaying, and discarded upon completion of that specific experimental run.

Comparative Analysis: Tesamorelin vs. CJC-1295, Sermorelin, and Ipamorelin

In preclinical metabolic and tissue-repair research, investigators often evaluate multiple secretagogues to establish comparative receptor kinetics, peak signal amplitude, and downstream organ response. Understanding the structural differences among these research compounds allows lab personnel to select the precise tool required for their active biological model.

Tesamorelin represents a modified full-length GHRH fragment (1-44) optimized specifically for metabolic regulation and IGF-1 axis modulation. In comparison, CJC-1295 No DAC (Tetrasubstituted GRF 1-29) is a shortened GHRH analog designed for rapid, transient pituitary receptor engagement. Another related GHRH derivative, Sermorelin, consists of the essential 29-amino-acid catalytic core (GHRH 1-29); while effective in demonstrating baseline GH release in vitro, Sermorelin exhibits a shorter half-life in biological media compared to trans-hexenoyl modified Tesamorelin.

To achieve synergistic GH release in dual-pathway research models, investigators frequently pair GHRH analogs with selective growth hormone secretagogue receptor (GHSR-1a) agonists such as Ipamorelin. While Tesamorelin acts directly through the GHRH pathway, Ipamorelin simulates ghrelin receptor activation without elevating baseline cortisol or prolactin markers in preclinical animal models, providing a dual-mechanism platform for advanced endocrinological studies.

Storage, Temperature Stability, and Handling Protocols

Unreconstituted (lyophilized) Tesamorelin 50mg vials must be stored in temperature-monitored environments to maintain chemical stability. For short-term storage (under 30 days), desiccated lyophilized vials remain stable at 2°C to 8°C. For long-term storage exceeding one month, vials should be kept frozen at -20°C or colder, isolated from light exposure and temperature fluctuations.

Prior to reconstitution, the lyophilized vial should be allowed to acclimate to room temperature inside a desiccator chamber. Adding cold diluent directly to a cold vial can create vacuum-driven condensation or osmotic stress, leading to localized peptide aggregation. Diluent should be introduced along the glass wall of the vial using a gentle, low-shear technique. Swirl the vial with smooth circular motions; never vortex or vigorously shake reconstituted peptide solutions, as mechanical agitation can disrupt the tertiary structure of sensitive amino acid chains.

Analytical Quality Verification: HPLC, MS, and Endotoxin Testing

High-mass peptide vials require rigorous analytical validation to ensure that absolute chemical purity and fill uniformity meet stringent quantitative research standards. Every production lot supplied by PX1 Research undergoes rigorous testing in an independent, ISO 17025 accredited laboratory to verify sequence identity and freedom from synthesis side-products.

Analytical protocols utilize High-Performance Liquid Chromatography (HPLC) to verify chromatographic purity (consistently target ≥98.0%) and Mass Spectrometry (MS) to confirm the exact molecular mass (4982.8 Da for Tesamorelin base). Furthermore, because high-mass vials are frequently used in cell culture or sensitive in vivo rodent assays, every lot undergoes Chromogenic LAL Endotoxin Testing to confirm endotoxin levels remain below strict limits (<0.05 EU/mg). Researchers can inspect these detailed analytical results directly by accessing our lot-matched COA database.

Determining Protocol Needs: Bulk Vials vs. Unit Formulations

Selecting between a 50mg bulk mass vial and smaller unit sizes (such as 10mg vials) depends heavily on the scale, duration, and specific parameters of the experimental protocol. High-throughput continuous screening assays, large cohort rodent studies, or central core facility stock requirements benefit from the unit-cost efficiency and lot-uniformity inherent to larger single-lot fills.

Conversely, protocols requiring infrequent assay runs or small sample sizes are better served by lower mass unit formats to avoid potential stability loss during extended fluid storage. Facilities requiring continuous, customized peptide supplies for large-scale institutional projects or laboratory supply contracts are invited to review our enterprise services via our wholesale portal to discuss customized lot reservations, bulk pricing structures, and specialized packaging configurations. All PX1 Research compounds are manufactured in cGMP-compliant US facilities and ship same-day (Monday through Friday) from our centralized distribution hubs in California and Arizona.